Ozren Jaksic
Overview
Explore the profile of Ozren Jaksic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aurer I, Jaksic O, Basic-Kinda S, Misura-Jakobac K, Sincic-Petricevic J, Novakovic-Coha S, et al.
Biomedicines
. 2025 Jan;
12(12.
PMID: 39767808
Obinutuzumab was approved for front-line treatment of chronic lymphocytic leukemia in combination with chlorambucil pulses administered every 2 wks. Alternative schedules of chlorambucil enable the administration of higher total chlorambucil...
2.
Chatzikonstantinou T, Scarfo L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, et al.
Hemasphere
. 2024 Sep;
8(9):e70004.
PMID: 39290716
No abstract available.
3.
Pantic N, Barac A, Mano V, Dedeic-Ljubovic A, Malkodanski I, Jaksic O, et al.
J Infect Public Health
. 2024 Jul;
17(8):102493.
PMID: 38970927
Background: In the Balkans, rising concerns about invasive fungal infections over the past decade stem from various factors. Primarily, there has been a notable uptick in immunocompromised individuals, including those...
4.
Lahmer T, Salmanton-Garcia J, Marchesi F, El-Ashwah S, Nucci M, Besson C, et al.
Infection
. 2024 May;
52(3):1191-1194.
PMID: 38771466
No abstract available.
5.
Aiello T, Salmanton-Garcia J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, et al.
Haematologica
. 2024 Apr;
109(8):2693-2700.
PMID: 38572549
No abstract available.
6.
Dragcevic D, Pandzic Jaksic V, Jaksic O
Arh Hig Rada Toksikol
. 2024 Mar;
75(1):24-31.
PMID: 38548376
As novel substances, short time windows, and limits of detection increasingly challenge direct methods of doping detection in sports, indirect tools inevitably take a greater role in the fight against...
7.
Salmanton-Garcia J, Marchesi F, Farina F, Weinbergerova B, Itri F, Davila-Valls J, et al.
EClinicalMedicine
. 2024 Mar;
71:102553.
PMID: 38533127
Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals,...
8.
Lucijanic M, Krecak I, Soric E, Sabljic A, Vasilj T, Cicic D, et al.
Scand J Clin Lab Invest
. 2024 Feb;
84(2):84-90.
PMID: 38414267
Secondary polycythemia is commonly observed among patients with chronic pulmonary diseases. However, its significance in the context of Coronavirus disease 2019 (COVID-19) is unknown. We retrospectively evaluated a total of...
9.
Aurer I, Jaksic O, Basic-Kinda S, Mrdenovic S, Ostojic-Kolonic S, Lozic D, et al.
Biomedicines
. 2024 Feb;
12(2).
PMID: 38397933
Patients with lymphoid malignancies are at increased risk of death or prolonged infection due to COVID-19. Data on the influence of different antineoplastic treatment modalities on outcomes are conflicting. Anti-CD20...
10.
Lahmer T, Salmanton-Garcia J, Marchesi F, El-Ashwah S, Nucci M, Besson C, et al.
Infection
. 2024 Feb;
52(3):1125-1141.
PMID: 38388854
No abstract available.